Cost Comparison of Recombinant Human Erythropoietin and Blood Transfusion in Cancer Chemotherapy-Induced Anemia
Authors:
- Reinée E SheffieldRSReinée E Sheffield
- Sean D SullivanSSSean D Sullivan
- Emmanuel SaltielESEmmanuel Saltiel
- Lyn NishimuraLNLyn Nishimura
- 1 January 1997
- journal article
- research article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 31 (1) , 15-22
Abstract
OBJECTIVE: To compare the cost of recombinant human erythropoietin (rHuEPO) with that of blood transfusion in the treatment of chemotherapy-induced anemia from a healthcare system perspective. DESIGN: A decision analytic model. Baseline estimates were obtained from a review of clinical trials data and economic evaluation studies. SUBJECTS: Secondary data analyses of patients with advanced malignancies, excluding hematologic malignancies and metastasized solid tumors. INTERVENTIONS: Patients received either leukocyte-depleted packed red blood cells (PRBCs) or rHuEPO 150 units/kg sc three times per week for 6 months (24 wk). After 6 weeks, if rHuEPO recipients did not display a response, they received rHuEPO 300 units/kg sc three times weekly for the duration of therapy. If rHuEPO recipients still exhibited no response, they were given blood transfusions. MEASUREMENTS AND MAIN RESULTS: For a treatment period of 24 weeks, approximately 64% of rHuEPO recipients responded at an average expected cost of $12 971 per patient. One hundred percent of transfusion recipients responded at a cost of $4481; this resulted in a cost savings of $8490. Variation of response rates for rHuEPO or PRBCs did not appreciably lower costs. Lower rHuEPO dosages and higher numbers of transfused units of PRBCs yielded approximately equivalent costs; however, these strategies may not be clinically prudent. CONCLUSIONS: From a healthcare system cost and outcome perspective, blood transfusion is the preferred strategy for chemotherapy-induced anemia. However, rHuEPO may be considered an effective blood-sparing alternative for patients with non-stem cell disorders. Future cost-effectiveness analyses are needed to assess more completely both the clinical and quality-of-life benefits rHuEPO may contribute to individual patients' lives and to society overall.Keywords
This publication has 47 references indexed in Scilit:
- Prophylaxis for Venous Thromboembolism in Hip Fracture SurgeryPharmacoEconomics, 1994
- Erythropoietin for anaemia in cancer patientsEuropean Journal of Cancer, 1993
- Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease.BMJ, 1992
- Phase I-II Trial of Erythropoietin in the Treatment of Cisplatin-Associated AnemiaJNCI: Journal of the National Cancer Institute, 1992
- Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysisAustralian and New Zealand Journal of Medicine, 1991
- Reports of 355 transfusion‐associated deaths: 1976 through 1985Transfusion, 1990
- Erythropoietin Treatment of Anemia Associated with Multiple MyelomaNew England Journal of Medicine, 1990
- Recombinant Human Erythropoietin for Patients with AIDS Treated with ZidovudineNew England Journal of Medicine, 1990
- The Natural History of Transfusion-Associated Infection with Human Immunodeficiency VirusNew England Journal of Medicine, 1989
- Exposure of Patients to Human Immunodeficiency Virus through the Transfusion of Blood Components That Test Antibody-NegativeNew England Journal of Medicine, 1989